TABLE 5.

E. lenta MIC ranges and susceptibility rates reported in the literature^a

Reference (yr)	No. of isolates	MIC range (mg/liter), % susceptibleb
		PEN	FOX	CRO	AMC	TZP	CLI	MOX	MET	ERT	MEM	TGC	VAN
53 (2013)	20								0.125 to 0.5				1 to 8
54 (2013)	10		8 to 16, 100			16 to 64, 90	0.25 to 0.5, 100		0.5 to 1, 100		1 to 2, 100	0.5
13 (2012)	8	1 to 4, 0				32 to 64, 87.5	0.5 to >32, 37.5	0.25 to >32, 75	1 to 2, 100		0.5, 100	0.12 to 0.25	0.5 to 2
55 (2009)	17				0.5 to 1	8 to 16	0 to >32		0.25 to 0.5
33 (2006)	10	≤0.06 to 4, 10	0.5 to 8, 100	≤0.12 to 256, 30	≤0.06 to 1, 100	≤0.12 to 32, 100	≤0.06 to 1, 100		0.12 to 1, 100		≤0.06 to 0.5, 100
6 (2005)	9	0.12 to 0.5*					0.12 to 0.5						0.5 to 1
56 (2005)	14					≤0.12 to 32						≤0.06 to 1	0.25 to 2
57 (2004)	10	≤0.03 to 0.5*				≤0.03 to 32							0.5 to 1
58 (2004)	20					0.25 to 32, 95	0.12 to 8, 90	0.03 to 1, 100	0.06 to 4, 100
59 (2003)	8	1*			1		0.06 to 0.25	0.25 to 0.5	≤0.125 to 0.5				1 to 2
60 (2003)	12	≤0.06 to 1*			≤0.06 to 2		≤0.06 to 0.5	≤0.06 to 1	≤0.06 to >64
61 (2003)	17	0.25 to 2*	1 to 16				≤0.03 to 1		0.125 to 1				0.5 to 2
62 (2002)	16			0.25 to >64		≤0.125 to 32	0.03 to >32		0.25 to >16	0.06 to 2	0.06 to 4
64 (1998)	Group A, 25	2,* 0		32 to 128, 0			0.5 to 4, 88		1 to 2, 100
	Group B, 6	0.5,* 100		1, 100			≤0.06, 100		1 to 2, 100

^aAll studies utilized CLSI agar dilution methodology and CLSI breakpoints.

^bPEN, penicillin (*, ampicillin); FOX, cefoxitin; CRO, ceftriaxone; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam; CLI, clindamycin; MOX, moxifloxacin; MET, metronidazole; ERT, ertapenem; MEM, meropenem; TGC, tigecycline; VAN, vancomycin.